Cerebrospinal Fluid Concentrations of Neurotransmitters in a Greek Pediatric Reference Population

Emmanouil Vilanakis; Evangelos Papakonstantinou; Efstathia Paramera; Ioanna Argyri; Eleni Drakou; Eleftheria Kokkinou; Vicky Zouvelou; Chrysa Outsika; Roser Pons

doi:10.1055/a-1988-2412

Neuropediatrics, Inhaltsverzeichnis

Neuropediatrics 2023; 54(02): 126-133
DOI: 10.1055/a-1988-2412

Original Article

Cerebrospinal Fluid Concentrations of Neurotransmitters in a Greek Pediatric Reference Population

Emmanouil Vilanakis

¹Pediatric Department, 401 General Military Hospital, Athens, Greece

²First Department of Pediatrics, National and Kapodistrian University of Athens, Agia Sofia Hospital, Athens, Greece

,

Evangelos Papakonstantinou

³Neolab SA Medical Laboratory, Athens, Greece

,

Efstathia Paramera

³Neolab SA Medical Laboratory, Athens, Greece

,

Ioanna Argyri

⁴Second Department of Pediatrics, National and Kapodistrian University of Athens, Aglaia Kyriakou Hospital, Athens, Greece

,

Eleni Drakou

²First Department of Pediatrics, National and Kapodistrian University of Athens, Agia Sofia Hospital, Athens, Greece

,

Eleftheria Kokkinou

²First Department of Pediatrics, National and Kapodistrian University of Athens, Agia Sofia Hospital, Athens, Greece

,

Vicky Zouvelou

²First Department of Pediatrics, National and Kapodistrian University of Athens, Agia Sofia Hospital, Athens, Greece

,

Chrysa Outsika

²First Department of Pediatrics, National and Kapodistrian University of Athens, Agia Sofia Hospital, Athens, Greece

,

Roser Pons

²First Department of Pediatrics, National and Kapodistrian University of Athens, Agia Sofia Hospital, Athens, Greece

› Institutsangaben

Abstract

Background Biogenic amines and pterins analysis in cerebrospinal fluid (CSF) are reliable biomarkers for the diagnosis of inherited disorders of monoamine neurotransmitters.

Objective The objectives of this study were the establishment of reference values of CSF biogenic amine metabolites in a cohort of Greek children, the detection of primary defects of biogenic amine metabolism, and the assessment of biogenic amine metabolites in children with different neurological disorders.

Methods CSF biogenic amine metabolites and pterins (biopterin and neopterin) were analyzed using high-performance liquid chromatography with electrochemical and fluorescence detection. Three hundred sixty-three samples were analyzed: 60 infants and children with no history of neurological disorder, 6 with inherited disorders of monoamine neurotransmitters, and 297 with diverse neurological disorders.

Results Reference values were stratified into six age groups. A strong correlation between homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) levels with age was detected (p < 0.001). Two patients were diagnosed with a defect of the biogenic amine synthetic pathway and three with a defect of tetrahydrobiopterin cofactor production. HVA and 5HIAA abnormalities were detected within different groups of neurological disorders, but none followed a specific pattern of HVA and 5HIAA abnormalities.

Conclusion In the current study, Greek reference values of biogenic amines and pterins in CSF are presented. Five new patients with inherited monoamine neurotransmitter disorders are described. Nonspecific secondary biogenic amine disturbances can be seen in patients with different neurological disorders.

Keywords

biogenic amines - neurotransmitters - dopamine - serotonin - biopterin - neopterin

Volltext

Referenzen

References
1 Kurian MA, Gissen P, Smith M, Heales Jr S, Clayton PT. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol 2011; 10 (08) 721-733
2 Batllori M, Molero-Luis M, Casado M, Sierra C, Artuch R, Ormazabal A. Biochemical analyses of cerebrospinal fluid for the diagnosis of neurometabolic conditions. What can we expect?. Semin Pediatr Neurol 2016; 23 (04) 273-284
3 Kandel ER, Schwartz JH, Jessell TM. Part7 BT—Principles of Neural Science, Fourth Edition. New York: McGraw-Hill; 2000. ;(44–51): 1-145
4 Hyland K. Neurochemistry and defects of biogenic amine neurotransmitter metabolism. J Inherit Metab Dis 1999; 22 (04) 353-363
5 Blau N. Disorders of Tetrahydrobiopterin And Related Biogenic Amines in the Metabolic and Molecular Bases of Inherited Disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B. eds. 8th ed. New York: McGraw-Hill; 2001
6 Hyland K. Clinical utility of monoamine neurotransmitter metabolite analysis in cerebrospinal fluid. Clin Chem 2008; 54 (04) 633-641
7 Kusmierska K, Jansen EEW, Jakobs C. et al. Sepiapterin reductase deficiency in a 2-year-old girl with incomplete response to treatment during short-term follow-up. J Inherit Metab Dis 2009; 32 (Suppl. 01) S5-S10
8 Marín-Valencia I, Serrano M, Ormazabal A. et al. Biochemical diagnosis of dopaminergic disturbances in paediatric patients: analysis of cerebrospinal fluid homovanillic acid and other biogenic amines. Clin Biochem 2008; 41 (16-17): 1306-1315
9 Seifert Jr WE, Foxx JL, Butler IJ. Age effect on dopamine and serotonin metabolite levels in cerebrospinal fluid. Ann Neurol 1980; 8 (01) 38-42
10 Pons R. The phenotypic spectrum of paediatric neurotransmitter diseases and infantile parkinsonism. J Inherit Metab Dis 2009; 32 (03) 321-332
11 Blennow K, Wallin A, Gottfries CG. et al. Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease. Neurobiol Aging 1992; 13 (01) 107-113
12 Wood JH. Sites of origin and cerebrospinal fluid concentration gradients. In: Neurobiology of Cerebrospinal Fluid 1. USA: Springer; 1980: 53-62
13 Ormazabal A, García-Cazorla A, Fernández Y, Fernández-Alvarez E, Campistol J, Artuch R. HPLC with electrochemical and fluorescence detection procedures for the diagnosis of inborn errors of biogenic amines and pterins. J Neurosci Methods 2005; 142 (01) 153-158
14 Molero-Luis M, Serrano M, Ormazábal A. et al; Neurotransmitter Working Group. Homovanillic acid in cerebrospinal fluid of 1388 children with neurological disorders. Dev Med Child Neurol 2013; 55 (06) 559-566
15 Kuster A, Arnoux JB, Barth M. et al; Individual contributors who contributed to this work. Diagnostic approach to neurotransmitter monoamine disorders: experience from clinical, biochemical, and genetic profiles. J Inherit Metab Dis 2018; 41 (01) 129-139
16 Horvath GA, Demos M, Shyr C. et al. Secondary neurotransmitter deficiencies in epilepsy caused by voltage-gated sodium channelopathies: a potential treatment target?. Mol Genet Metab 2016; 117 (01) 42-48
17 Hyland K, Surtees RAH, Heales SJR, Bowron A, Howells DW, Smith I. Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population. Pediatr Res 1993; 34 (01) 10-14
18 Keller M, Brennenstuhl H, Kuseyri Hübschmann O. et al; International Working Group on Neurotransmitter related Disorders (iNTD). Assessment of intellectual impairment, health-related quality of life, and behavioral phenotype in patients with neurotransmitter related disorders: data from the iNTD registry. J Inherit Metab Dis 2021; 44 (06) 1489-1502
19 Kuseyri Hübschmann O, Mohr A, Friedman J. et al; International Working Group on Neurotransmitter Related Disorders (iNTD). Brain MR patterns in inherited disorders of monoamine neurotransmitters: an analysis of 70 patients. J Inherit Metab Dis 2021; 44 (04) 1070-1082
20 Kuseyri Hübschmann O, Horvath G, Cortès-Saladelafont E. et al; iNTD Registry Study Group. Insights into the expanding phenotypic spectrum of inherited disorders of biogenic amines. Nat Commun 2021; 12 (01) 5529
21 Pons R, Serrano M, Ormazabal A. et al. Tyrosine hydroxylase deficiency in three Greek patients with a common ancestral mutation. Mov Disord 2010; 25 (08) 1086-1090
22 Willemsen MA, Verbeek MM, Kamsteeg E-J. et al. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain 2010; 133 (Pt 6): 1810-1822
23 Pons R, Syrengelas D, Youroukos S. et al. Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency. Mov Disord 2013; 28 (08) 1058-1063
24 Friedman J, Roze E, Abdenur JE. et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol 2012; 71 (04) 520-530
25 Opladen T, López-Laso E, Cortès-Saladelafont E. et al. Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies. Orphanet J Rare Dis 2020; 15 (01) 1-30
26 Furukawa Y, Lang AE, Trugman JM. et al. Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. Neurology 1998; 50 (04) 1015-1020
27 Segawa M, Nomura Y, Nishiyama N. Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease). Ann Neurol 2003; 54 (Suppl. 06) S32-S45
28 García-Cazorla A, Serrano M, Pérez-Dueñas B, González V, Ormazábal A, Pineda M, Fernández-Alvarez E, Campistol JM, Artuch RM. Secondary abnormalities of neurotransmitters in infants with neurological disorders. Dev Med Child Neurol 2007; (10) 740-744
29 De Grandis E, Serrano M, Pérez-Dueñas B. et al. Cerebrospinal fluid alterations of the serotonin product, 5-hydroxyindolacetic acid, in neurological disorders. J Inherit Metab Dis 2010; 33 (06) 803-809
30 Tonduti D, Zorzi G, Ghezzi D, Zibordi F, Garavaglia B, Nardocci N. Cerebrospinal fluid monoamine metabolite analysis in pediatric movement disorders. J Child Neurol 2015; 30 (13) 1800-1805

Zusatzmaterial

Supplementary Material